Clinical Trial Update: Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating VB10.16 in combination with pembrolizumab for HPV-positive oropharyngeal squamous cell carcinoma and head-and-neck squamous cell ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Hpv-positive Oropharyngeal Squamous Cell Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• VB10.16

Snippet

Sponsor: Nykode Therapeutics ASA | Conditions: HPV Positive Oropharyngeal Squamous Cell Carcinoma, HNSCC | Phase 1, Phase 2 | Status: RECRUITING